drugset / Trial / NCT00184613

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

NCT00184613

Phase 1 Completed 22 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.

Timeline

Start
2005-05
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin aspart Protein / enzyme biologic Subcutaneous
Subject insulin glargine Protein / enzyme biologic